JP Morgan resumed coverage on Orchard Therapeutics
$ORTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
JP Morgan resumed coverage of Orchard Therapeutics with a rating of Overweight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/29/2021 | $12.00 → $9.00 | Overweight | Cantor Fitzgerald |
| 11/16/2021 | Neutral → Underweight | JP Morgan | |
| 11/5/2021 | $15.00 → $13.00 | Outperform | Oppenheimer |
| 8/18/2021 | Overweight → Neutral | JP Morgan |
4 - Orchard Therapeutics plc (0001748907) (Issuer)
4 - Orchard Therapeutics plc (0001748907) (Issuer)
4 - Orchard Therapeutics plc (0001748907) (Issuer)